Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

15.6K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
15.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Leaky Scanning02:28

Leaky Scanning

5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Improving Translational Accuracy02:07

Improving Translational Accuracy

11.9K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.

Nature cancer·2026
Same author

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Blood advances·2026
Same author

Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia.

Cancer research·2026
Same author

Maternal trans-vaccenic acid shapes neonatal T cell development and early-life immune imprinting.

Science (New York, N.Y.)·2026
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Spatially resolved m<sup>6</sup>A profiling using m<sup>6</sup>A-ARTR-DBiT.

Nature methods·2026
Same journal

DNA, Peptide Vaccines Advance Against GBM.

Cancer discovery·2026
Same journal

AKR1C1 Promotes ADC Resistance by Altering Uptake and Export.

Cancer discovery·2026
Same journal

Acquisition of Centromeric Features Supports Telomere Integrity.

Cancer discovery·2026
Same journal

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Sep 13, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation.

Chao Shen1,2, Yuan Che1, Keren Zhou1

  • 1Department of Systems Biology and Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Monrovia, California.

Cancer Discovery
|August 1, 2025
PubMed
Summary
This summary is machine-generated.

ALKBH1 overexpression drives acute myeloid leukemia (AML) by enhancing codon-biased translation and mitochondrial function, promoting cancer growth and drug resistance. Targeting ALKBH1 offers a novel therapeutic strategy for AML.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K
Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling
10:00

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling

Published on: October 28, 2014

28.4K

Related Experiment Videos

Last Updated: Sep 13, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K
Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling
10:00

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling

Published on: October 28, 2014

28.4K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Epigenetics

Background:

  • Cancer cells exploit codon-biased translation for growth and drug resistance.
  • Mechanisms driving these processes in acute myeloid leukemia (AML) are not fully understood.

Purpose of the Study:

  • Investigate the role of ALKBH1 in AML pathogenesis and drug resistance.
  • Elucidate the molecular mechanisms by which ALKBH1 influences cancer cell biology.

Main Methods:

  • Analysis of ALKBH1 expression in AML patient samples.
  • Functional studies in leukemia stem/initiating cells (LSC/LICs).
  • Investigation of ALKBH1's impact on mitochondrial function and oxidative phosphorylation (OXPHOS).

Main Results:

  • ALKBH1 is overexpressed in AML and crucial for LSC/LIC self-renewal and AML development.
  • ALKBH1 enhances mitochondrial function, supporting AML survival and resistance to venetoclax.
  • ALKBH1 catalyzes 5-formylcytosine (f5C) on tRNA, facilitating codon-biased translation and oncogenic protein synthesis.

Conclusions:

  • ALKBH1 plays a critical role in AML by reprogramming translation and enhancing mitochondrial metabolism.
  • Targeting ALKBH1, alone or with venetoclax, shows promise as an anti-leukemia therapy.